ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. Show More...

  • Website http://www.proqr.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.66 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -0.15 -1.09 -0.89 -1.67 -1.72 -1.08 -1.38 -1.34
    Dividends EUR
    Payout Ratio % *
    Shares Mil 22.0 11.0 23.0 23.0 25.0 34.0 41.0 44.0
    Book Value Per Share * USD 5.79 4.48 2.78 1.22 3.02 1.35 1.79
    Free Cash Flow Per Share * USD -0.57 -1.13 -1.65 -1.68 -1.03 -1.19
    Return on Assets % -134.37 -20.25 -19.35 -47.21 -73.56 -45.18 -49.59 -56.88
    Financial Leverage (Average) 1.05 1.11 1.23 1.35 1.19 1.24 1.27
    Return on Equity % -22.19 -20.92 -54.71 -94.35 -55.78 -60.33 -71.63
    Return on Invested Capital % -104.57 -20.82 -20.24 -50.61 -80.32 -49.58 -53.3 -61.67
    Interest Coverage -84.61 -44.76 -51.74 -71.68 -72.28 -44.78 -51.28
    Current Ratio 1.18 37.79 17.82 9.24 5.95 13.28 10.43 11.04
    Quick Ratio 1.18 37.65 17.57 9.06 5.72 13.2 10.29 10.82
    Debt/Equity 0.03 0.05 0.11 0.13 0.1 0.13 0.16